Genome editing can bypass issues related to the inability to produce sufficient CAR-T cells from autologous sources via the generation of allogeneic universal “off-the-shelf” CAR-T cells by KO of components of the TCR and the HLA, such as the TCRα and TCRβ constant chains (TRAC and TRBC) and beta-2 microglobulin (B2M), respectively.73 Simultaneous editing of TCR genes reduces the risk of GVHD in the allogeneic setting. Here, B2M is linked to graft versus host disease.